Perioden saknade större order Under det tredje kvartalet steg omsättningen med 38% till 227 mkr (164...
Solid Q3-rapport visar på styrka i fokus på nischprodukter En stark volymutveckling och en god kostn...
Redeye see a Q3 2023 report from Nanologica that came in lower than we had projected in terms of sal...
Vaisala posted Q3 results with net sales slightly below our expectations, yet EBIT was very strong a...
CapMan’s Q3 was below estimates mainly due to carry and FV changes.
Redeye concludes that Heliospectra’s Q3 report was somewhat weaker than anticipated in terms of both...
Omsättningen kom in högre än förväntat men vinsten är fortsatt under press.
Redeye shares its initial thoughts on Netmore’s Q3 report, which showed impressive sales growth, pri...
Suominen’s result improved from Q2, albeit slightly less than factored in consensus estimates, and m...
- 10% org. sales (ABGSCe 14%), 9% EBIT decline - Cons 2023e EBIT roughly unchanged (excl.
Q3 confirms that Vitrolife is going through a period with softer organic growth, even below our expe...
Redeye sees a solid Q3 report from Fortnox, with strong growth in Pengar and robust net customer int...
Redeye think that Sdiptech’s Q3 report was stronger than our expectations, with both Resource Effici...
Redeye is happy to see firm top-line growth around 20%, coupled with clearly higher gross margins th...
- Adj. EBITA SEK 22.9m (+8% vs. ABGSCe 21.3m) - Q3 numbers imply +2% adj.
- Largest owner Norvik hf (59%) offers SEK 44.5 per share - Offer constitutes an 86% premium to clos...
Redeye comments on the Q3 report released earlier this morning.
Redeye states that Doro’s Q3 2023 report was much stronger than Redeye's expectation on every item.
Redeye sees a solid Q3 report from Proact despite sales and EBITA coming in slightly short of our ex...
Net sales and operating profit were 1% below consensus (Refinitiv) in Q3.
